NIHON TRIM CO.,LTD.
6788・Prime Market・Electric Appliances
Water Healthcare Business
Core business accounting for approximately 87% of consolidated net sales, centered on alkaline ionizer sales and bottled water
| Period | Current | Previous | Change |
|---|---|---|---|
| Segment sales (full year) | ¥21,135 million | ¥19,565 million | ↑ |
| Segment profit (full year) | ¥2,711 million | ¥2,895 million | ↓ |
| Segment profit margin (full year) | 12.8% | 14.8% | ↓ |
| Segment assets (fiscal year end) | ¥26,439 million | ¥25,894 million | ↑ |
| Depreciation (full year) | ¥341 million | ¥329 million | ↑ |
| Domestic alkaline ionizer sales | ¥9,242 million | up 1.8% year on year | ↑ |
| Domestic cartridge sales | ¥5,836 million | up 4.2% year on year | ↑ |
| Indonesia bottled water sales | ¥4,785 million | up 29.2% year on year | ↑ |
Business Details
The Company mainly manufactures and sells the Electrolyzed Hydrogen Water Alkaline Ionizer (a controlled medical device), while also operating the water purification cartridge stock business (a consumable item), wholesale & OEM sales, and a bottled water business in Indonesia (PT. SUPER WAHANA TEHNO). The Company promotes customer acquisition through a combined channel approach of workplace sales (DS Division) and wholesale/OEM (MS Division), with cartridge sales forming a stable earnings base.
Recent Overview
Sales reached a record high, but profit declined 6.4% year on year due to increased personnel investment, advertising expenses, and raw material costs
Water Healthcare Business sales for FY2026 (ending March 2026) were ¥21,135 million (up 8.0% year on year), a new record high. On the other hand, segment profit was ¥2,711 million (down 6.4% year on year). The main causes of the profit decline were expanded personnel investment (increase in sales personnel in the DS Division), increased advertising expenses in the Indonesian bottled water business, and increased raw material cost burden due to the surge in platinum prices used in the electrode plates of alkaline ionizers. For FY2027 (ending March 2027), the Company plans segment sales of ¥23,560 million (up 11.5% year on year) and segment profit of ¥3,188 million (up 17.6% year on year), representing increased sales and profit.
Key Products
Growth Drivers
- Expansion of the bottled water business of PT. SUPER WAHANA TEHNO in Indonesia (enhanced TV commercials and SNS advertising, and strengthened production capacity and management efficiency through the new proprietary factory expected to begin operation during FY2027)
- Growth of the domestic cartridge sales stock business (stable earnings expansion through enhanced regular customer services)
- Expansion of sales channels through increased sales personnel in the workplace sales division (DS Division) (targeting a workforce of 150 within the current fiscal year, up 22.0% from the previous fiscal year end)
- Increased demand for alkaline ionizers driven by heightened awareness of water safety amid the PFOS/PFOA issue (the Company's cartridges' organofluorine compound removal performance is a key selling point)
- Expansion of alkaline ionizer demand driven by rising health and beauty consciousness amid the gut health boom
- Steady progress in developing new sales channels in the sports, beauty, and financial institution sectors
Risks
- Increased selling, general and administrative expenses due to expanded personnel investment (increase in sales staff, regular salary raises) pressuring profit margins
- Short-term profit reduction due to upfront marketing investment (TV commercials, SNS advertising costs) in Indonesia
- Risk of increased raw material costs due to the surge in platinum prices used in alkaline ionizer electrode plates and rising prices of petroleum-related raw materials stemming from the Middle East situation (already factored into the FY2027 (ending March 2027) forecast)
- Risk of a slowdown in sales to existing distributors in the wholesale/OEM division (MS Division) (acquiring new major distributors and expanding overseas transactions are challenges)
- Foreign exchange risk in the Indonesian business (foreign currency translation adjustment was ¥-16,218 thousand for the fiscal year)
- Risk of delays in the construction and commencement of operations of the new proprietary factory in Indonesia (targeting operation to begin during FY2027)
Last updated: June 22, 2026